



Partner Profile

Novartis AG provides healthcare solutions that address the evolving needs of patients and societies. Novartis Vaccines & Diagnostic is an independent division of Novartis AG. Novartis globally produces over 500 million doses of vaccine annually (70% to developing countries) and has over 20 vaccines in development. As a leader in scientific innovation (i.e. adjuvants, reverse vaccinology, and flu-cell culture), the company has significant R&D investments focused on meningitis, influenza, and other vaccine-preventable diseases. Novartis is the major supplier of UNICEF and Pan-American Health Organization and collaborates with international associations such as the Global Alliance for Vaccines and Immunization (GAVI) and World Health Organization (WHO).

Websites: www.novartisvaccines.com

Role in the ADVANCE Project

The main scientific contributions for the ADVANCE project will be provided by the Novartis departments of Epidemiology and Public Affairs. Novartis will contribute to the overall scientific and project coordination in the roles of Deputy coordinator of EFPIA, Steering committee member and EFPIA Coordinator of WP2.

Key People



John Weil, MD. Head of Epidemiology. Experienced health professional with thirty years of postgraduate experience in hospital general medicine, academic clinical epidemiology, public health medicine and the pharmaceutical industry. In industry has applied epidemiology methodology to contribute to all stages of drug and vaccine development, with a focus on methods for post-licensure observational studies.



Mendel Haag, PhD. Principal Epidemiologist. Clinical epidemiologist (PhD 2009) with specific expertise in pharmacoepidemiology. As Principal Epidemiologist at Novartis her primary responsibility pertains to post-marketing observational studies, which have included secondary database studies, pregnancy registries and a serosurvey. Involved in

pharmacovigilance legislation implementation working groups.
